Drug class
Fully human monoclonal antibody; fibroblast growth factor 23 (FGF23) inhibitor
Mechanism of action
Binds FGF23 and inhibits its biological activity, restoring renal tubular phosphate reabsorption and increasing renal production of 1,25-dihydroxyvitamin D. This increases serum phosphate availability for bone mineralisation.
General use cases
- Treatment of X-linked hypophosphataemia (XLH) in eligible adults and children aged 6 months and older, according to product-specific age and clinical criteria
- Treatment of tumour-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised, in eligible adults and paediatric patients aged 2 years and older under the applicable US label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
